Modified DNA cleavage enzymes and methods for use
View Patent ↗Compositions and methods are provided that relate to a modified DNA cleaving enzyme having at least 35% amino acid sequence identity with T7 Endo I. The modified enzyme includes two catalytic centers separated by a β-bridge where the β-bridge contains at least one mutation having an effect of altering enzyme cleavage activity compared to the unmodified enzyme. Activities associated with the modified DNA cleaving enzyme that can be modulated in different reaction conditions include at least one of: (a) non-sequence specific nicking activity; (b) cleaving the second strand of a duplex DNA at a preexisting nick site to produce a linear duplex with a single strand overhang; (c) non-sequence specific DNA cleavage; (d) cleaving DNA flanking a mismatch; and (e) cleavage at a cruciform structure in a DNA duplex.
1. A composition, comprising:
a variant T7 Endo I polypeptide having endonuclease activity, and comprising an amino acid sequence that differs from the amino acid sequence of its parent T7 Endo I polypeptide solely by one or more mutations in a β-bridge corresponding to amino acids 44-49 of SEQ ID NO: 12.
2. The composition according to claim 1 , wherein the endonuclease activity comprises greater DNA cleavage activity of the variant T7 Endo I polypeptide in a manganese-containing buffer compared with the DNA cleavage activity of the parent T7 Endo I polypeptide in the manganese-containing buffer.
3. The composition according to claim 2 , wherein the DNA cleavage activity is selected from the group consisting of: cleavage of a cruciform DNA; nicking opposite a preexisting nick site; nicking next to a mismatch in the DNA resulting in double strand cleavage; and non-specific nuclease activity.
4. The composition according to claim 1 , wherein the endonuclease activity comprises reduced DNA cleavage activity of the variant T7 Endo I polypeptide in a magnesium-containing buffer compared with the DNA cleavage activity of the parent T7 Endo I polypeptide in the magnesium-containing buffer.
5. The composition according to claim 4 , wherein the DNA cleavage activity is selected from the group consisting of: nicking opposite a preexisting nick site; nicking next to a mismatch in the DNA resulting in double strand cleavage; and non-specific nuclease activity.
6. The composition according to claim 1 , wherein the one or more mutations is a substitution or a deletion at a site corresponding to a Pro-Ala (PA) dipeptide in the β-bridge corresponding to amino acids 44-49 of SEQ ID NO:12.
7. The composition according to claim 6 , wherein the substitution is a single amino acid substitution, a dipeptide substitution, a tripeptide substitution, or a tetrapeptide substitution; or wherein the deletion is a deletion of the PA dipeptide, deletion of Pro, or deletion of Ala.
8. The composition according to claim 7 , wherein the PA dipeptide is substituted with an Ala (A), a Lys (K), a Gly (G), an Asp (D), a Pro (P), an Ala-Ala (AA) dipeptide, an Ala-Gly-Ala (AGA) tripeptide, or a Pro-Ala-Pro-Ala (PAPA) peptide.
9. A kit comprising the composition of claim 6 .
10. A method of forming a shotgun cloning library, comprising:
(a) incubating the composition of claim 1 with a DNA to form non-sequence specific cleavage fragments of the DNA that are ligatable; the ligatable DNA being capable of insertion into a vector for cloning into a vector for cloning in a host cell; and
(b) forming the shotgun cloning library.
11. A method for mapping nicks in a duplex DNA, comprising:
(a) incubating the composition of claim 1 with the duplex DNA in a manganese-containing buffer;
(b) permitting nicking to occur across from a pre-existing nick site to form fragments of the duplex DNA with single strand overhangs; and
(c) mapping the nicks in the DNA.